Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement

S Petersenn, M Fleseriu, FF Casanueva… - Nature Reviews …, 2023 - nature.com
Abstract This Consensus Statement from an international, multidisciplinary workshop
sponsored by the Pituitary Society offers evidence-based graded consensus …

Male infertility

A Agarwal, S Baskaran, N Parekh, CL Cho, R Henkel… - The Lancet, 2021 - thelancet.com
It is estimated that infertility affects 8–12% of couples globally, with a male factor being a
primary or contributing cause in approximately 50% of couples. Causes of male subfertility …

[PDF][PDF] Position statement for clinical practice: prolactin-secreting tumors

R Cozzi, MR Ambrosio, R Attanasio… - European Journal of …, 2022 - research.unipd.it
Prolactinomas are the most frequent pituitary adenomas. Prolactinoma may occur in different
clinical settings and always require an individually tailored approach. This is the reason why …

Pituitary adenoma or neuroendocrine tumour: the need for an integrated prognostic classification

KKY Ho, UB Kaiser, P Chanson, M Gadelha… - Nature Reviews …, 2023 - nature.com
In the 2022 fifth edition of the WHO Classification of Endocrine Tumours and of Central
Nervous System Tumours, pituitary adenomas are reclassified as neuroendocrine tumours …

Adrenal insufficiency: physiology, clinical presentation and diagnostic challenges

J Martin-Grace, R Dineen, M Sherlock, CJ Thompson - Clinica chimica acta, 2020 - Elsevier
Adrenal insufficiency (AI) is a serious condition, which can arise from pathology affecting the
adrenal gland itself (primary adrenal insufficiency, PAI), hypothalamic or pituitary pathology …

Prevalence and clinical correlations of SF3B1 variants in lactotroph tumours

J Simon, LG Perez-Rivas, Y Zhao… - European journal of …, 2023 - academic.oup.com
Objective A somatic mutational hotspot in the SF3B1 gene was reported in lactotroph
tumours. The aim of our study was to examine the prevalence of driver SF3B1 variants in a …

Update in pathogenesis, diagnosis, and therapy of prolactinoma

N Fukuhara, M Nishiyama, Y Iwasaki - Cancers, 2022 - mdpi.com
Simple Summary This review updates recent advances in the pathogenesis, diagnosis, and
therapy of prolactinoma. Prolactinomas, comprising 30–50% of all pituitary neuroendocrine …

Italian Association of Clinical Endocrinologists (AME) and International Chapter of Clinical Endocrinology (ICCE). Position statement for clinical practice: prolactin …

R Cozzi, MR Ambrosio, R Attanasio… - European journal of …, 2022 - academic.oup.com
Prolactinomas are the most frequent pituitary adenomas. Prolactinoma may occur in different
clinical settings and always require an individually tailored approach. This is the reason why …

Pituitary surgery as alternative to dopamine agonists treatment for microprolactinomas: a cohort study

B Baussart, C Villa, A Jouinot… - European Journal of …, 2021 - academic.oup.com
Objective Microprolactinomas are currently treated with dopamine agonists. Outcome
information on microprolactinoma patients treated by surgery is limited. This study reports …

Incidence, demographics, and survival of patients with primary pituitary tumors: a SEER database study in 2004–2016

C Chen, Y Hu, L Lyu, S Yin, Y Yu, S Jiang, P Zhou - Scientific reports, 2021 - nature.com
Comprehensive investigations on the incidence and prognosis of pituitary tumors are still
lacking. The present study aims to summarize the incidence, demographics, and survival …